BSD Medical Reports Initiation Of Clinical Study By University of Utah School of Medicine, Huntsman Cancer Center, Using Microthermx®: Microwave Ablation System To Treat Liver Tumors

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced initiation of a clinical study by the University of Utah School of Medicine using BSD’s MicroThermX® Microwave Ablation System (MicroThermX) to treat liver tumors. The study is a prospective, non-randomized, single arm trial that involves 20 patients. The study objective is to clinically evaluate the size of the ablation zones produced in liver tissue by BSD’s patented Synchronous Wave Alignment™ technology developed for MicroThermX. Both cirrhotic and non-cirrhotic liver tissue will be evaluated in this clinical study. The study is open for patient enrollment at the University of Utah School of Medicine. The principal investigator for the study is Ryan O’Hara, M.D., Assistant Professor of Radiology, Chief, Department of Interventional Radiology, Director of Interventional Oncology, University of Utah School of Medicine, Huntsman Cancer Hospital.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC